| 1 |
34272716 | Case Study 9: Probe-Dependent Binding Explains Lack of CYP2C9 Inactivation by 1-Aminobenzotriazole (ABT). | 2021 |
1 |
| 2 |
32219694 | In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions. | 2020 Jun |
2 |
| 3 |
32279279 | The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions. | 2020 Dec |
1 |
| 4 |
32941854 | Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy. | 2020 Nov 1 |
1 |
| 5 |
28960974 | A Chemoproteomic Platform To Assess Bioactivation Potential of Drugs. | 2017 Oct 16 |
1 |
| 6 |
26481538 | Inhibition of human cytochrome P450 isoenzymes by a phenothiazine neuroleptic levomepromazine: An in vitro study. | 2015 Dec |
2 |
| 7 |
27747722 | Diclofenac- and Pantoprazole-Induced Rhabdomyolysis: A Potential Drug Interaction. | 2015 Dec |
1 |
| 8 |
18838506 | Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection. | 2009 Jan |
1 |
| 9 |
18634893 | Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. | 2008 Nov-Dec |
1 |
| 10 |
18034666 | Effect of voriconazole on the pharmacokinetics of diclofenac. | 2007 Dec |
5 |
| 11 |
16192110 | Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes. | 2005 Jun |
1 |
| 12 |
11037108 | Characterization of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates. | 2000 Aug |
1 |